296 related articles for article (PubMed ID: 26138001)
1. Distinctive Effect of Donepezil Treatment on P300 and N200 Subcomponents of Auditory Event-Related Evoked Potentials in Alzheimer Disease Patients.
Vaitkevičius A; Kaubrys G; Audronytė E
Med Sci Monit; 2015 Jul; 21():1920-7. PubMed ID: 26138001
[TBL] [Abstract][Full Text] [Related]
2. Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer's disease: a case-control study.
Chang YS; Chen HL; Hsu CY; Tang SH; Liu CK
J Clin Neurophysiol; 2014 Feb; 31(1):81-5. PubMed ID: 24492450
[TBL] [Abstract][Full Text] [Related]
3. Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.
Thomas A; Iacono D; Bonanni L; D'Andreamatteo G; Onofrj M
Clin Neuropharmacol; 2001; 24(1):31-42. PubMed ID: 11290880
[TBL] [Abstract][Full Text] [Related]
4. The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease.
Reeves RR; Struve FA; Patrick G; Booker JG; Nave DW
Am J Geriatr Psychiatry; 1999; 7(4):349-52. PubMed ID: 10521169
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer's disease.
Katada E; Sato K; Sawaki A; Dohi Y; Ueda R; Ojika K
J Geriatr Psychiatry Neurol; 2003 Mar; 16(1):39-43. PubMed ID: 12641372
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Werber AE; Klein C; Rabey JM
Neurol Neurochir Pol; 2001; 35 Suppl 3():37-43. PubMed ID: 12001652
[TBL] [Abstract][Full Text] [Related]
7. Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.
Onofrj M; Thomas A; Luciano AL; Iacono D; Di Rollo A; D'Andreamatteo G; Di Iorio A
Clin Neuropharmacol; 2002; 25(4):207-15. PubMed ID: 12151908
[TBL] [Abstract][Full Text] [Related]
8. The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
Werber EA; Gandelman-Marton R; Klein C; Rabey JM
J Neural Transm (Vienna); 2003 Jun; 110(6):659-69. PubMed ID: 12768361
[TBL] [Abstract][Full Text] [Related]
9. The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia.
Onofrj M; Thomas A; Iacono D; Luciano AL; Di Iorio A
Clin Neuropharmacol; 2003; 26(5):239-51. PubMed ID: 14520164
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of event-related potentials in the assessment of mild cognitive impairment.
Papaliagkas V; Kimiskidis V; Tsolaki M; Anogianakis G
BMC Neurosci; 2008 Nov; 9():107. PubMed ID: 18986528
[TBL] [Abstract][Full Text] [Related]
11. Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease.
Cancelli I; Cadore IP; Merlino G; Valentinis L; Moratti U; Bergonzi P; Gigli GL; Valente M
J Clin Neurophysiol; 2006 Oct; 23(5):421-5. PubMed ID: 17016152
[TBL] [Abstract][Full Text] [Related]
12. Cognitive predictors of donepezil therapy response in Alzheimer disease.
Saumier D; Murtha S; Bergman H; Phillips N; Whitehead V; Chertkow H
Dement Geriatr Cogn Disord; 2007; 24(1):28-35. PubMed ID: 17495473
[TBL] [Abstract][Full Text] [Related]
13. P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia.
Paci C; Gobbato R; Carboni T; Sanguigni S; Santone A; Curatola L
Neurol Sci; 2006 Feb; 26(6):435-7. PubMed ID: 16601937
[TBL] [Abstract][Full Text] [Related]
14. Associations of event-related brain potentials and Alzheimer's disease severity: A longitudinal study.
Fruehwirt W; Dorffner G; Roberts S; Gerstgrasser M; Grossegger D; Schmidt R; Dal-Bianco P; Ransmayr G; Garn H; Waser M; Benke T
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():31-38. PubMed ID: 30582941
[TBL] [Abstract][Full Text] [Related]
15. Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease.
Kuzmickienė J; Kaubrys G
Med Sci Monit; 2015 Aug; 21():2572-82. PubMed ID: 26336931
[TBL] [Abstract][Full Text] [Related]
16. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
[TBL] [Abstract][Full Text] [Related]
17. The role of event-related potentials in cognitive decline in Alzheimer's disease.
Lai CL; Lin RT; Liou LM; Liu CK
Clin Neurophysiol; 2010 Feb; 121(2):194-9. PubMed ID: 20005164
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
19. [Evoked potentials N200/P300 disorders and clinical phenotype in Cuban families with paranoid schizophrenia: a family-based association study].
Guerra López S; Martín Reyes M; Pedroso Rodríguez Mde L; Reyes Berazain A; Mendoza Quiñones R; Bravo Collazo TM; Días de Villarvilla T; Machado Cano MJ; Bobés León MA
Medwave; 2015 Apr; 15(3):e6112. PubMed ID: 25919584
[TBL] [Abstract][Full Text] [Related]
20. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Wattmo C; Minthon L; Wallin ÅK
Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
